This clinical trial is focused on studying a condition known as Chronic Graft Versus Host Disease (cGVHD). This is a complication that can occur after a stem cell or bone marrow transplant, where the donated cells attack the recipient’s body. The treatment being tested in this study is a medication called Axatilimab, which is given as a solution through an intravenous infusion. The study aims to evaluate the effectiveness, safety, and tolerability of Axatilimab at three different doses in patients who have cGVHD that has not responded to at least two previous treatments.

Participants in the study will receive Axatilimab at one of three doses: 0.3 mg/kg every two weeks, 1 mg/kg every two weeks, or 3 mg/kg every four weeks. The study will observe how well the treatment works and monitor any side effects. The goal is to see if Axatilimab can help reduce the symptoms of cGVHD and improve the quality of life for those affected by this condition.

The study will take place over a period of time, with regular check-ups and assessments to track the participants’ progress. This includes monitoring vital signs, conducting physical examinations, and evaluating the response to the treatment. The information gathered from this study will help determine the potential benefits of Axatilimab for patients with cGVHD who have limited treatment options.